GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway.

Dawei Rong,Yuliang Wang,Li Liu,Hengsong Cao,Tian Huang,Hanyuan Liu,Xiaopei Hao,Guangshun Sun,Guoqiang Sun,Zhiying Zheng,Junwei Kang,Yongxiang Xia,Ziyi Chen,Weiwei Tang,Xuehao Wang

Journal for immunotherapy of cancer（2023）

引用 4|浏览19

暂无评分

摘要

Our study revealed that GLIS1 promoted CD8 T cell exhaustion in HCC through transcriptional regulating SGK1-STAT3-PD1 pathway. Downregulating the expression of GLIS1 in CD8 T cells exerted an effect with anti-PD1 treatment synergistically, revealing a prospective method for HCC immune therapy.

查看译文

关键词

biomarkers, tumor,drug therapy, combination,immunity, cellular

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要